California’s top cannabis regulator has said the US Drug Enforcement Administration (DEA) has given states no formal guidance on how to implement the Trump administration’s decision to move some marijuana products to a less restrictive federal category, as first reported by Marijuana Moment.

Clint Kellum, director of the California Department of Cannabis Control, spoke at a meeting of the state’s Cannabis Advisory Committee on Tuesday. “We have received no formal updates from DEA headquarters on implementation guidance of the order,” he said.

Requests for data

Mr Kellum said the department had tried to contact DEA headquarters to understand what rules operators would be expected to follow. He said regulators from other states had also made “national-level efforts” to reach the agency, but had not seen “any sort of interest” in return.

At the same time, he said, the DEA has asked California for data on medicinal cannabis production and dispensing. The state has asked what the figures will be used for and would like to explain its market to the agency. He said that in California, people identifying themselves as medical users is “not really incentivized”, so without knowing how the data would be used the state had not been able to share information as it would like.

Mr Kellum said that other states were starting to see DEA inspections of businesses that had registered under the new arrangements. He said the agency appeared to be concentrating on states with clear medical cannabis programmes rather than “mixed states” such as California, and that there seemed to be regional variation in the approach.

Background

In April, US Attorney General Todd Blanche issued an order moving marijuana products regulated under a state medical cannabis licence, along with products approved by the Food and Drug Administration, from Schedule I of the Controlled Substances Act to Schedule III. A separate DEA hearing on broader rescheduling has recently finished hearing testimony. The DEA has also launched a form for cannabis businesses to register for federal protections linked to the change.

In May, California’s department adopted initial emergency rule changes to its licensing process, intended to make it easier for businesses to qualify for benefits in line with the federal move.

Mr Kellum said the state would wait for further federal guidance before making more changes. “The last thing what we want to do is try to be guessing what they’re going to be doing,” he said, adding that the department wanted to be “methodical”. He said regulators were tracking four developments for material changes: DEA guidance, the outcome of the wider rescheduling hearing, Internal Revenue Service guidance on tax issues for cannabis businesses, and legal challenges to the reform. He added that officials would spend time this autumn considering the effect on international and interstate commerce.

Other state officials have raised similar complaints. James Pepper, chair of the Vermont Cannabis Control Board, said earlier this year that regulators could not “effectively advise our licensees”. The report was also summarised in Marijuana Moment’s newsletter on 22 September.

Why it matters in the UK

The US is a large and closely watched cannabis market, and changes to federal law there affect research, investment and the international debate on cannabis policy. In the UK, cannabis remains a Class B drug under the Misuse of Drugs Act 1971, though specialist doctors have been able to prescribe cannabis-based medicines since 1 November 2018.